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a b s t r a c t
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or their
therapies. Immunotherapy has gained a lot of interest in the past few years and has recently gained
approval as first line therapy in multiple advanced stage malignancies. Pneumonitis has been described
as complication of such therapy. Granulomatous inflammation has been only rarely reported subsequent
to immunotherapy. We describe a case of granulomatous inflammation reactivation affecting the lungs in
a patient previously exposed to Pembrolizumab and have evidence of a distant granulomatous infection.
We discuss potential mechanisms of the inflammation and assert the importance of immunosuppression
in controlling the dis-inhibited immune system.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Two drug antibodies targeting the programmed cell death 1
(PD-1) pathway are currently approved by the US food and drug
administration for treatment of patients with advanced malig-
nancies [1]. Systemic toxicities associated with their use such as
pyrexia, chills, generalized fatigue, insulin depended diabetes,
dermatitis, alveolitis and infusion reaction have been commonly
reported [2]. Most of these complications are thought related to
autoimmune phenomena. Only few cases have been reported a link
of pulmonary sarcoidosis with this class of medications.
2. Case report
Our patient is a 65-year-old white female. Her past medical
history is significant for stage III, T3B, N2A superficial Melanoma on
the left buttock. This was treated with surgical removal of the tu-
mor with the ipsilateral inguinal lymph node (LN). She has evi-
dence of old granulomatous disease in the form of bilateral
granulomas some of which where calcified along with hilar lymph
node calcifications and splenic calcifications. Pembrolizumab was
used as part of a trial for one year. She presented to the walk in
clinic with worsening productive cough of white sputum with
neither fever nor hemoptysis. Chest x ray showed possible pul-
monary metastasis versus pneumonia (Fig. 1). She was admitted for
investigations of the abnormalities. Vital signs and physical exam
were normal except for decreased air entry on the right lower zone.
Complete blood count showed chronic leukocytosis and mild
anemia. Chemistry panel was significant for hypomagnesaemia,
hypokalemia, and hypoalbuminemia. Patient was started on anti-
biotics for possible pneumonia. Blood culture, mycoplasma DNA,
legionella urine antigen, acid-fast bacilli (AFB) and sputum culture
came back negative. Chest computed tomography (CT) scan ob-
tained due to worsening hypoxemia needing 5 L of oxygen flow per
minute showed lower lobes consolidation, and bilateral hilar and
mediastinal lymphadenopathy. Multiple lucencies surrounding the
splenic calcifications were noted (Fig. 2a, b, c). An immune reaction
to chemotherapy was considered and patient consented to bron-
choscopy with endobronchial ultrasound (EBUS) guided biopsy of
the lymph nodes for suspicion of sarcoidal reaction. White light
bronchoscopy did not show any endobronchial lesions or anoma-
lies. Bronchoalveolar lavage (BAL) and transbronchial parenchymal
biopsies were obtained from the right lower lobe. The patient
developed severe bronchospasm that precluded sampling the
lymph nodes. The patient was started on high dose intravenous
steroids and showed dramatic clinical improvement. Biopsy result
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showed chronic granulomatous inflammation with histocytes with
no malignancy identified (Fig. 3a, b).
Given the lack of evidence for infection, and the bilateral hilar
and mediastinal adenoapthy along with the granulomatous
inflammation obtained from the biopsy, the patient was diagnosed
with pulmonary sarcoidal reaction secondary to pembrolizumab.
The patient was discharged on 40mg daily oral steroids. Onemonth
follow up CT scan chest was done showed resolution of the pleural
effusion and near complete resolution of the lower zone air space
disease (Fig. 4 A, B). Due to the long lasting effect of PD-1 pathway
inhibition the patient is being evaluated for a prolonged and slow
taper of oral steroids to prevent recurrence.
3. Discussion
Immunotherapy for cancer treatment has been well established
through multiple clinical trials for various malignancies [1,2]. Given
their relatively young age in clinical practice, experience regarding
the complications and side effects of this relatively new therapy in
everyday practice is not well known. Multiple diseases that are
considered related to heightened autoimmunity have been re-
ported after their use [3]. For instance, Type I Diabetes Mellitus,
exacerbation of psoriasis, vitiligo, and interstitial nephritis to name
a few. Sarcoidosis, whether de novo or as reactivation of an existing
disease, has only been reported twice after the use of PD-1 in-
hibitors pathway [4,5].
Non-caseating Granulomatous inflammation is considered a
type IV immune reaction [6]. It forms as the activated T lympho-
cytes, induced by a foreign antigen, secrete a specific set of in-
terleukins and chemo attractants [6]. Sarcoid like reaction is a term
used to describe granulomatous inflammation found in the setting
of active cancer or after the delivery of effective chemotherapy [7].
Sarcoid like reactions has been confused with recurrent metastatic
disease due to high PET avidity of the lymph nodes involved. Of
Interest is that sarcoid like reactions are asymptomatic and are only
diagnosed incidentally during follow-ups for cancer therapy [7].
The exact mechanism of sarcoidal reaction is not really known. It is
likely different depending on the type of malignancy treated and
the type of cancer treatment being implemented. For instance,
granulomatous inflammation associated with active cancer could
Fig. 1. Chest x ray showing bilateral infiltrate and hilar adenopathy.
Fig. 2. a: CT chest shows left lower lobe infiltrate (arrow) with right pleural effusion. b; CT chest showing the left lower lobe infiltrate. c: CT abdomen shows heterogeneity of the
spleen due to granulomatous disease (arrow).
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be an attempt of the body to control themalignancy and “wall it in”.
The same inflammation after treatment of lymphoma might be
seen as a reconstitution of normal immunity [8]. Following cancer
therapy, the sarcoidal reaction could be a response of the body to
the cancer antigens that were secreted in the blood or as a side
effect of the chemotherapy causing damage to certain tissue
inducing the granulomatous inflammation. Other therapies like
interferon and IL-2 can induce such a sarcoidal reaction due to their
direct effect on activating lymphocytes and macrophages [9].
The case of PD-1 pathway inhibition is somewhat different.
Preclinical studies have shown that PD-1 blockade reinvigorated
exhausted T-cell that has been suppressed by repeated exposure to
the PD-1 ligand. The lifting of inhibition induced by these biologics
restores T-cell cytotoxic and other immune functions [10]. Blockade
of the PD1 pathway by Pembrolizumab resulted in a reproducible
enhancement of both proliferation and IFN-g release in the mixed
lymphocyte reaction. It is well known that the secretion of inter-
feron gamma is essential for the formation of granulomatous dis-
ease even in the absence of intact T cells [9]. This data indicates that
a blockade of PD1, increases IFN-g secretion from memory T cells,
and could explain a sarcoid-like reaction.
In our case, the granulomatous inflammation was only noted in
the pneumonia-like infiltrate in the right lower lobe. It is unlikely
for Sarcoidosis to result in such a pneumonic infiltrate. The pres-
ence of mediastinal and hilar lymphadenopathy is classic for
sarcoidosis [11]. The lymph nodes could not biopsied, however, due
to the complication during bronchoscopy. It is possible that the
lymphadenopathy could have been reactive to the parenchymal
inflammation rather than true involvement with the disease pro-
cess <. Infectious etiologies are unlikely given the negative cultures
for fungal or bacterial or mycobacterial elements. One more note to
make is that our patient had evidence of granulomatous inflam-
mation in the form of a calcified pulmonary granuloma. This is a
very common finding in regions of Ohio and Mississippi river val-
leys [12,13]. The patient responded immediately after the first dose
of steroids and her hypoxia reversed without oxygen on the 4th day
after steroid initiation. The important difference in our case from
the known sarcoidal reaction, is the fact that this form of inflam-
mation was very symptomatic and life threatening inducing hyp-
oxic respiratory failure. The presentation with a pneumonic type of
inflammation and pleural effusion was highly atypical for sarcoid-
osis. Based on these factors, we speculate that our patient suffered
from a granulomatous reaction. As noted previously, this patient
likely had previously suppressed T lymphocytes based on prior
exposure to a foreign antigen, resulting in the calcified granulomas.
We suggest that exposure to Pembrolizumab, lifted the inhibition of
these suppressed T lymphocytes resulting in reactivation of the
underlying disease process. Suppressing these lymphocytes again
by the use of steroids has restored part of their inhibition/tolerance.
This remains a speculation but the fact that the inflammation was
centered on the calcifications (healed granuloma) in both lungs and
spleen makes that speculation a very valid one.
4. Conclusion
In linewith the increased use of anti-PD1 agents, it appears to be
important for clinicians to be aware of this new potential immune-
mediated toxic effect. Therapy with PD-1 inhibitors can awaken the
memory T-cells against previous targets for which tolerance has
developed including prior granulomatous disease.
Fig. 3. A. Hematoxylin & eosin stain (400) Histiocytes (black arrow), neutrophils, lymphocytes, histiocytes (red arrow), and fibrin (green arrow) Figure 3b CD68 immunohis-
tochemical antibody, DAB chromogen (400) Stain (brown color) highlights histiocytes.
Fig. 4. a: follow up chest CT shows resolution of the left lower lobe infiltrate, resolution of the left pleural effusion, notice the calcification of the left lower lobe (arrow). Figure 4b:
follow up CT abdomen after Pembrolizumab has been stopped and patient has been shows remnant splenic calcification (arrow).
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